echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The 2nd paragraph in the country!

    The 2nd paragraph in the country!

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On November 29, Junshi Bio announced that the clinical trial application for Aurora A inhibitor WJ05129 tablets (JS112) of Suzhou Junjing Bio (which jointly invested with Weijing Bio) has been accepted by NMPA


    Aurora A, a member of the serine/threonine protein kinase in the Aurora kinase family, plays an important role in the process of cell mitosis


    JS112 is an oral small-molecule Aurora A inhibitor, which has a synthetic lethal effect with RB1 gene deletion or inactivation, and can be used to treat malignant tumors with RB1 deletion or inactivation such as small cell lung cancer and triple-negative breast cancer


    At present, there is no Aurora A inhibitor approved for marketing in the world


    Medicine Rubik's Cube NextPharma

    In China, in October this year, the clinical application for the Aurora A inhibitor VIC-1911 of Jisi Yingda was accepted by the NMPA


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.